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miR-155 is an oncogenic microRNA with well described roles in leukemia.  However, 
additional roles of miR-155 in breast cancer progression have recently been described. 
A thorough literature search was conducted to review all published data to date 
examining the role of miR-155 in breast cancer.  Data on all validated miR-155 target 
genes was collated to identify biological pathways relevant to miR-155 and breast 
cancer progression. Publications describing the clinical relevance, functional 
characterisation, and regulation of expression of miR-155 in the context of breast 
cancer are reviewed.  147 validated miR-155 target genes were identified from the 
literature.  Pathway analysis of these genes identified likely roles in apoptosis, 
differentiation, angiogenesis, proliferation and EMT. The large number of validated 
miR-155 targets presented here provide many avenues of interest as to the clinical 
potential of miR-155.  Further investigation of these target genes will be required to 
elucidate the specific mechanisms and functions of miR-155 in breast cancer. This is 
the first review examining the role of miR-155 in breast cancer progression.  The 
collated data of target genes and biological pathways of miR-155 identified in this 
review suggest new avenues of research for this oncogenic microRNA. 
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Introduction 
MicroRNAs (miRNAs) are small noncoding RNAs which control expression of target 
genes by either inhibiting protein translation or directly targeting mRNA transcripts of 
target genes for degradation (1).  Each miRNA has a specific seed sequence 7-8 
nucleotides long, which directly binds to complementary sequences in regulatory 
regions of target genes. These binding regions are often in the 3’ UTR of target genes, 
but increasingly are being reported in other non-coding regions such as promoter or 
intronic regions (2).  The short length of the seed sequence facilitates the targeting of 
many transcripts by a single miRNA (3).  The biological relevance of miRNAs have 
increasingly been recognised in recent years, with some estimates suggesting that 
30% of all eukaryotic genes are regulated by miRNAs (4; 5).  miR-155 is a miRNA 
widely published to be involved in lymphoma, but in more recent years evidence has 
also emerged for it playing a role in the progression of solid cancers (6).  This review 
will focus on the microRNA miR-155, and its role in breast cancer.   
 
miRNAs were discovered in 1993 when the C.elegans lin-4 gene, which is transcribed 
but not translated, was found to regulate levels of LIN-14 protein (7; 8).  Since this 
discovery there have been over 500 miRNAs described, regulating a wide range of 
genes and cellular processes, although the total predicted number of unique miRNAs 
encoded by the human genome is estimated to be over 1000 (9). Many of these 
miRNAs are organised as gene clusters and transcribed as multicistronic messages – 
for example, the MIRH1 gene encodes 6 different miRNAs (10). The transcription and 
processing of miRNAs has been well characterised, and is depicted in Figure 1 using 
miR-155 as an example.  miRNAs originate from a ~70 nucleotide RNA hairpin pre-
miRNA processed from the RNA transcript of the host gene (11) (in the case of miR-
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155, the host gene BIC).  The pre-miRNA is typically cleaved by the Drosha and 
Dicer exonucleases into a ~22 nucleotide RNA duplex. One strand of the duplex 
becomes the mature miRNA and is usually the functional, regulatory unit (12; 13) 
while the other is designated miR* and is usually degraded. The mature miRNA is 
loaded into Argonaute proteins, forming the RNA Induced Silencing Complex 
(RISC). The mature miRNA may then bind to its target by partial complementarity of 
target gene mRNA and either inhibit translation or cause degradation of the mRNA.  
 
The miR-155 host gene, BIC, was first described in 1989 and postulated to be 
involved in the progression of lymphoma (14).  In 2002, Lagos-Quintana et al 
identified miR-155 as a regulatory RNA (15).  Since this discovery, the role of miR-
155 has been extensively studied in lymphoma (16-19), and has also been implicated 
in regulating genes involved in viral infection, cardiovascular disease and solid 
cancers (6; 20-22). miR-155 has over 400 predicted gene targets (23) and more than 
100 confirmed bona fide targets involved in pathways such as apoptosis and cancer 
progression.  In recent years, there has been an emerging role of miR-155 in breast 
cancer progression, as seen by a number of recent studies (20; 21; 24). This article 
will review the current literature regarding miR-155 and breast cancer, and discuss 
both predicted and validated target genes of miR-155. 
 
Clinical Relevance of miR-155 in Breast Cancer 
The expression level of miR-155 has been found to be upregulated in breast cancer in 
several studies. In some cases high levels of miR-155 have also been associated with 
clinicopathological markers, tumour subtype and poor survival rates. These findings 
are summarised in Table 1. 
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Numerous studies have found an association with increased miR-155 levels in breast 
cancer tissue.  Of 29 miRNAs found to be dysregulated in breast cancer, the majority 
were downregulated, with only miR-155 and miR-21 significantly upregulated (25). 
Expression levels of 15 of these dysregulated miRNAs could be used to independently 
predict the invasive potential of independently analysed breast tissue samples (25). A 
small microarray study of 8 fresh breast tumour samples compared to normal adjacent 
tissue found miR-155 was upregulated in the breast tumours (34).  Kong et al. 
conducted two studies investigating the role of miR-155 in breast cancer. Firstly, 62 
breast carcinomas were analysed to determine miR-155 levels. Out of 17 non-invasive 
tumours, only 2 (12%) exhibited a high level of miR-155 expression. Conversely, 41 
of the 45 invasive tumours (91%) displayed miR-155 upregulation (32). The second 
study investigated expression levels of miR-155 target gene FOXO3A in 77 primary 
breast tumours, 38 recurrent tumours and 11 normal tissue samples. This found that 
miR-155 was upregulated and FOXO3A downregulated in a majority of primary 
tumours, and also that high miR-155 and low FOXO3A expression was associated 
with recurrent tumours after radiotherapy or chemotherapy (21). These studies linked 
miR-155 expression to both invasiveness and recurrence of breast tumours, and 
demonstrated that expression levels of miR-155 and its specific target genes are of 
potential clinical prognostic value.   
 
In a robust study that included 363 breast tumour samples, Volinia et al. globally 
compared miRNA expression levels in multiple tumour and pooled normal tissue 
samples to identify dysregulated miRNAs in tumour samples.  This was performed for 
a wide range of tumours including lung, breast, stomach, prostate, colon and 
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pancreatic. Comparisons of normal and tumour tissue derived from each individual 
tissue were conducted and miR-155 expression was found to be upregulated in breast, 
colon and lung cancers. Interestingly, miR-155 was one of only two miRNAs (the 
other being the miR-200 family) found to be upregulated in both breast and lung 
cancer, implying that these microRNAs may be part of a common mechanism in the 
development of cancer in these organs (26). 
 
Other studies have found miR-155 expression levels to be associated with metastasis 
events and invasive properties of breast cancer.  One such study found that increased 
miR-155 expression is associated with high tumour grade, advanced tumour stage and 
lymph node metastasis (31). Disease free and overall survival were also negatively 
correlated with miR-155 levels, further showing the potential of miR-155 as a miRNA 
of clinical interest. These findings were further supported by two studies involving 
microarray analyses of FFPE breast cancer samples, which found that miR-155 
expression was upregulated in the malignant breast cancer (28, 33). 
 
Because of the relationship between miR-155 and poor prognosis and/or metastasis, a 
similar relationship between miR-155 and clinicopathological markers would be 
expected, and is indeed the case. Numerous studies have found links between 
hormone receptor status of tumours and miR-155 expression levels.  Blenkiron et al. 
analysed miRNA levels alongside mRNA levels, enabling classification of tumour 
subtype and identification of clinicopathological factors. In 93 breast cancer samples 
miR-155 levels were significantly upregulated in basal-like tumours and estrogen 
receptor negative (ER-) tumours (27), although no proposal for the mechanism of this 
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association is given. The correlation with basal-like tumours has clinical relevance 
due to the poor prognosis of this tumour subtype.  
 
Similarly, studies have investigated whether serum samples could be used to identify 
aberrant miRNA expression levels in breast cancer patients. In a small study of 21 
patients Zhu et al. found that multiple miRNAs could be detected in sera and the 
miRNA levels correlated with the levels in tissue samples (29). They also found that 
miR-155 was expressed at a higher level in the serum of PR+ breast cancer patients 
than in the serum of PR- patients (29).  Following these studies, Wang et al. 
conducted an in-depth study into miRNA levels in breast cancer using both fresh 
tumour and sera samples. The correlation of miRNA expression between tissue and 
matched serum samples was significant (R2=0.853). They confirmed that miR-155 
was upregulated in breast cancer, and also found that high miR-155 associated with 
grade II and III tumours, as well as ER- and PR- tumours (30). The detection of miR-
155 expression levels in serum could be a useful clinical prognostic indicator of 
tumour grade and hormone receptor status. This study reproduced the finding that 
miR-155 was expressed at higher levels in ER- tumours (27), but contradicted the 
study showing miR-155 levels to be higher in the serum of progesterone receptor 
positive (PR+) tumours (29). The topic of serum miRNAs is somewhat controversial, 
with some studies similarly suggesting that serum miRNA levels are robust (35; 36), 
and others claiming that miRNAs often used as normalisation controls are highly 
variable in sera samples, and thus miRNA quantification in sera is not reproducible 
(37). This might be an indicator that analysis of serum alone is not sufficient to 
determine whether miR-155 is differentially expressed. Additionally, the low number 
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of samples used in some of these studies could indicate that a more robust study is 
required before a conclusion can be made. 
 
Taken together, these studies show that miR-155 expression is upregulated in breast 
cancer, consistent with its status as an oncomiR. In addition, the association between 
miR-155 and a more invasive breast tumour has been identified in multiple studies. 
However, between studies the relationships between miR-155 and clinicopathological 
markers such as ER and PR status and tumour subtype is somewhat inconsistent. For 
example, the upregulation of miR-155 expression in PR+ tumours was only identified 
in one study that analysed a small number of samples (29). The mechanism linking 
miR-155 and hormone receptors remains unknown and further study is required to 
elucidate the mechanism and significance of these observations. 
 
Functional characterisation of miR-155 oncogenic activities in breast cancer 
An important step in determining the clinical significance of a molecule such as miR-
155, is to determine whether high expression levels are causally related to the 
development of breast cancer. Kong et al. assessed the effects of altering miR-155 
expression levels in a panel of breast cancer cell lines in vitro (21).  miR-155 
expression was inhibited by anti-miR in HS578T cells. An anti-miR is a 2′-O-methyl 
oligoribonucleotide that inhibits the action of a miRNA. One proposed mechanism for 
anti-miR action is antisense binding to the mature miRNA positioned in the RISC 
(38). The HS578T cell line expresses high levels of endogenous miR-155, and anti-
miR-155 application resulted in cell cycle arrest and induction of apoptosis, 
implicating miR-155 in these processes (21). Conversely, ectopic overexpression of 
miR-155 in BT474 cells, which express very low levels of endogenous miR-155, 
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promoted cell proliferation and survival and also improved chemoresistance (21). 
Taken together, these findings demonstrate that miR-155 has a role in cell 
proliferation and apoptosis, two cellular processes frequently aberrant in cancer. 
Similar results have also been reported in breast cancer cell lines MDA-MB-231 and 
MCF7 where ectopic miR-155 overexpression can increase proliferation, while 
inhibition of miR-155 expression by a specific anti-miR inhibits proliferation and 
increases radio-sensitivity of cells in vitro (20; 31).  
 
The first study of miR-155 in immunodeficient mice xenografted with human breast 
cancer cells confirmed that miR-155 acts as an oncomiR in vivo. Xenograft tumours 
established with MDA-MB-231 cells expressing anti-miR-155 displayed reduced 
tumour volume compared to control xenografts. In addition, overexpression of miR-
155 in MDA-MB-231 xenografts accelerated tumour growth (20). Similar results 
were obtained using a xenograft of MDA-MB-468 cells, which are low in endogenous 
miR-155 expression: tumour growth was accelerated when miR-155 was 
overexpressed (24). The same study also used an orthotopically transplantated mouse 
tumour cell line, where knockdown of miR-155 inhibited tumour growth (24). 
Contrary to this, a recent study using the 4T1 mouse mammary model showed that 
miR-155 had no effect on growth of the primary tumour (39).  
Although it has been widely shown that miR-155 is upregulated in breast cancer, the 
cause of aberrant miR-155 levels is not well characterised. When Kong et al. treated 
NMuMG cells with TGFβ they found miR-155 to be strongly upregulated (32). TGFβ 
can drive epithelial to mesenchymal transition (EMT), the process by which immobile 
epithelial cells alter their morphology to become motile mesenchymal cells and 
promote invasion (40). As EMT can be important in cancer progression (41; 42) they 
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investigated the role of miR-155 in TGFβ mediated EMT using NMuMG cells. It was 
found that Smad4, a key signalling molecule in the TGFβ pathway, can bind to the 
BIC promoter and enrich miR-155 expression levels, thereby augmenting the TGFβ 
EMT process (32). Knockdown of miR-155 in NMuMG cells by anti-miR suppressed, 
and ectopic overexpression of miR-155 enhanced TGFβ-mediated EMT (32). 
Furthermore a key molecule in EMT, RhoA, is a target of miR-155, and expression of 
RhoA is reduced when miR-155 is ectopically expressed. When RhoA was expressed 
without its 3`UTR (containing the miR-155 seed sequence) the EMT phenotype 
caused by miR-155 was abrogated (32). The ability to reverse a severe phenotypical 
change by reexpressing just one of the targets of miR-155 alludes to a potential 
therapeutic approach. Many miRNAs are known to have a role in metastasis and EMT 
(43), so in light of these findings it is plausible the basis of miR-155 in promoting 
breast cancer, in particular the higher grade invasive breast cancers, is from the 
promotion of EMT. However, the findings from the 4T1 mouse model contest the 
findings of Kong et al in NMuMG . Unfortunately both of the cell lines are of mouse 
origin. A miR-155 target gene in a mouse model will not necessarily be a target gene 
in humans, as the 3`UTR region of transcripts is a common location for miRNA seed 
sequences, and is not highly conserved between mice and humans. These conflicting 
results call into question the suitability of using a mouse-specific model for a miRNA 
study. 
 
Regulation of miR-155 expression 
Perhaps the most remarkable recent finding in relation to the role of miR-155 in breast 
cancer is the involvement with BRCA1.  BRCA1, the breast cancer susceptibility 
gene, is involved in DNA damage repair and cell cycle progression.  Mutations of 
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BRCA1 are associated with a high risk of developing breast cancer (24). In a recent 
study, the R1699Q BRCA1 mutant caused mouse embryonic stem cells to undergo 
spontaneous differentiation. The mutant cells displayed high levels of miR-155, and 
overexpression of miR-155 in BRCA1 wild type cells gave a similar phenotype to the 
mutant, indicating that BRCA1 was acting through miR-155 (24). In mice, a loss of 
functional BRCA1 resulted in miR-155 upregulation. These results were recapitulated 
in human cell lines, with deficient BRCA1 have 50-fold higher miR-155 levels 
compared to those with functional BRCA1 (24). Furthermore, the transient 
overexpression of BRCA1 in BRCA1 deficient cell lines reduces expression of miR-
155.  In clinical samples it was found that miR-155 levels were two to six fold higher 
in BRCA1 mutant tumours (24).  The mechanism of BRCA1 regulation of miR-155 
was through direct binding of BRCA1 protein to the miR-155 promoter. This in turn 
recruits histone deacetylase (HDAC) to repress the expression of BIC and thus miR-
155 (24).  This close association with the breast cancer susceptibility gene reinforces 
the importance of miR-155 in breast cancer. 
 
Target genes of miR-155 
Although miR-155 clearly has a role to play in breast cancer, microRNAs have 
limited function other than inhibiting expression of their target mRNAs. Therefore, 
ultimately it is the target genes and their inhibition that has an effect on cellular 
processes. Critical to understanding the role of miR-155 in breast cancer is identifying 
miR-155 target genes, specifically those target genes important in breast cancer.  
 
Several in silico prediction software programs are commonly used to identify putative 
target genes of particular miRNAs.  Targetscan is one such commonly used software, 
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which predicts target genes of miRNAs by alignment of the 7 or 8 nucleotide seed 
sequence with the 3’ UTR of 30,858 human transcripts based on conservation 
between human and mouse sequence (23).  Using this program, Targetscan version 6 
predicts 440 potential miR-155 targets (conserved) (23; 44).  However these targets 
are only predicted based on sequence homology, and must be tested in vitro before 
being considered true miR-155 target genes.  To this end, an extensive literature 
search was conducted to identify published validated miR-155 target genes. 
Validation was defined as a specific luciferase 3`UTR reporter assay for the target 
gene together with at least one other quantitative method to assess the repression of 
the endogenous expression levels of the target, such as qRT-PCR or Western blot 
analysis. Validation by luciferase 3`UTR reporter assays was considered an essential 
criterion for miR-155 targets, to ensure that miR-155 in fact directly targets the 
transcript for repression. The second criterion, validation by at least one other 
quantitative method, ensures that miR-155 has an effect on expression of the target 
gene.  
 
Table 2 displays a comprehensive list of 147 validated target genes identified in a 
wide range of miR-155 studies, and their prediction status by Targetscan. 103 target 
genes (including 11 target genes validated in other studies) were identified in a single 
high throughput next generation sequencing (NGS) study and validated by luciferase 
reporter assay (50). The remaining 44 target genes were validated by luciferase assay 
and at least one other method. Of the validated miR-155 target genes, approximately 
half (48%) were predicted to be targets by Targetscan software (23; 44). This 
highlights the drawbacks in relying on in silico prediction tools to investigate 
potential miRNA targets. The discrepancy between predicted and observed miR-155 
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binding sites is affected by miR-155 targeting non-conserved sites in target genes, as 
TargetScan by default searches for seed sequences conserved between human and 
mouse. Performing a Targetscan search irrespective of site conservation predicts 2390 
potential miR-155 targets, and encompasses all but 9 validated target genes. This is 
the first comprehensive collation of all known miR-155 target genes, and could be a 
valuable resource for future reference and research. 
 
Although only a fraction of these miR-155 target genes were validated in the context 
of breast cancer, a number of the targets are involved in cancer-related pathways such 
as apoptosis, proliferation and EMT (20; 21; 32; 88; 89).  miR-155 target genes 
involved in cancer-related pathways are shown in Figure 2.  The presence of validated 




As an oncomiR, expression levels of miR-155 are consistently upregulated in breast 
tumour samples. Some studies have associated miR-155 with clinical markers, more 
aggressive tumours and even decreased survival. It is clear from these studies that 
miR-155 is of clinical significance in breast cancer.  However, some contradictory 
findings have been noted, for instance the varied association of miR-155 with 
hormone receptor positive/negative tumours. It is also unclear as to whether miR-155 
is an initiator of cancer, or if it just promotes tumour progression. In a mouse model 
miR-155 has been shown to transform B-cells (90) but in breast cells has only been 
shown to enhance cancerous properties of tumour cells. More investigation is required 
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to fully understand the significance of aberrantly high levels of miR-155 in breast 
cancer. 
 
Exploration of the function of miR-155 in both xenograft models of breast cancer and 
breast cancer cell lines has shown that miR-155 enhances tumour growth, promotes 
cell proliferation, inhibits apoptosis and acts as a mediator of TGFβ-driven EMT.  The 
role of miR-155 in EMT in particular has promising therapeutic potential, given that 
miR-155 levels have been shown to be elevated in invasive tumour and in breast 
tumour metastases.  The large number of validated miR-155 targets presented here 
(Table 2) provide many avenues of further investigation as to the clinical potential of 
miR-155.  The further investigation of these targets will be required to confirm the 
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Tables 
miR-155 Tissue type Ref 
↑ in breast cancer  76 Breast tumour 
10 Normal breast 
(25) 
↑ in breast cancer 363 Breast tumour 
177 Normal breast  
(26) 
↑ in ER- tumours 93 Breast tumour 
5 Normal breast 
(27) 
↑ in malignant breast tissue 34 Breast tumour 
6 Normal Breast 
(28) 
↑ in PR+ tumours Serum – 13 breast cancer patients, 8 healthy 
patients 
(29) 
↑ in grade II and III tumours 
↑ in ER- PR- tumours 
Tumour, normal adjacent tissue and serum 
from 68 breast cancer patients 
Tissue and serum from 40 healthy patients 
(30) 
Associated with higher tumour grade, advanced 
tumour stage, lymph node metastasis 
92 Breast tumour and normal adjacent tissue (31) 
↑ in 41 of 45 invasive 
↑ 2 of 17 noninvasive tumours 
45 Invasive breast tumour 
17 Noninvasive breast tumour 
(32) 
↑ in 55 breast tumours 
↑ 31 recurrent tumours 
77 breast tumour 
11 Normal breast 
38 Recurrent breast tumour 
(21) 
↑ in breast metastases 13 Breast tumour and paired metastasis (33) 
↑ in tumours 8 Breast tumour and normal adjacent tissue (34) 
 
 Table 1 –Studies examining miR-155 expression in breast cancer 
Displayed are sample tissue type, number of samples in each study and a brief summary 
of the miR-155 related findings. 
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AGTR1 (AT1R) NM_000685  X  (45-48)  
AICDA (AID) NM_020661.2 X   (49)  
ANAPC16 (C10orf104) NM_173473.2  X  (50) 
APAF1 NM_013229.2  X  (50) 
ARID2 NM_152641 X   (50; 51)  
ARL15 NM_019087.2  X  (50) 
ARL6IP5 NM_006407.3  X  (50) 
ARMC2 NM_032131.4  X  (50) 
ARNT NM_001668  X X (52)  
BACH1 NM_206866 X   (50-52) 
BCL2 NM_000633.2  X  (53)  
BCORL1 NM_021946.4 X   (50) 
C10orf26 NM_001083913.1 X   (50) 
C16orf62 NM_020314.4  X  (50) 
C3orf18 NM_016210.4 X   (50) 
C5orf44 NM_001093755.1  X  (50) 
CARD11 NM_032415.3 X   (50) 
CARHSP1 NM_014316.2 X   (50) 
CASP3 NM_004346  X X (54)  
CCDC41 NM_016122.2  X  (50) 
CDC40 NM_015891.2  X  (50) 
CEBPB NM_005194 X   (51; 52; 55-57)  
CHD9 NM_025134.4 X   (50) 
CIAPIN1 NM_020313.2  X  (50) 
CKAP5 NM_001008938.1  X  (58)  
CLUAP1 NM_015041.1  X  (50) 
CREB1 (CREB) NM_004379.3 X   (59)  
CSF1R (CD115) NM_005211 X   (52)  
CSNK1A1 NM_001025105.1  X  (50) 
CTLA4 NM_005214 X   (60)  
CUX1 (CUTL1) NM_181552 X   (52)  
CYP2U1 NP_898898.1  X  (50) 
DCUN1D2 NM_001014283.1  X  (50) 
DET1 NM_017996.3 X   (50) 
DHX40 NM_024612.4 X   (50) 
E2F2 NM_004091.2 X   (50) 
EIF2C4 NM_017629.2 X   (50) 
ETS1 NM_001143820 X   (48; 50)  
EXOSC2 NM_014285.5  X  (50) 
FADD NM_003824  X X (54; 61)  
FAM135A NM_001105531.2 X   (50) 
FAM177A1 NM_173607.3  X  (50) 
FAM199X (CXorf39) NM_207318.2  X  (50) 
FAM91A1 NM_144963.2  X  (50) 
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FGF7 (KGF) NM_002009 X   (62)  
FOXO3 (FOXO3A) NM_001455 X   (21; 63)  
GABARAPL1 NM_031412.2  X  (50) 
GATM NM_001482.2  X  (50) 
GCET2 (HGAL) NM_152785.4  X  (64)  
GCFC1 (C21orf66) NM_016631.3 X   (50) 
GNAS NM_016592.2 X   (50) 
GOLT1B NM_016072.4  X  (50) 
HBP1 NM_012257.3 X   (50) 
HIF1A NM_001530  X  (52)  
HIVEP2 NM_006734 X   (50; 51; 57)  
IGJ NM_144646.3  X  (50) 
IKBKE (IKKE) NM_014002 X   (61; 65)  
IL13RA1 NM_001560  X X (66)  
IL17RB NM_018725.3  X  (50) 
INPP5D (SHIP1) NM_001017915 X   (67-71)  
INPP5F NM_014937.2  X  (50) 
INTS6 NM_012141.2  X  (50) 
IRAK3 (IRAKM) NM_007199  X X (72)  
JARID2 NM_004973 X   (50; 52; 73)  
KBTBD2 NM_015483.2  X  (50) 
KIAA0430 NM_014647.3  X  (50) 
KIAA1274 NM_014431.2 X   (50) 
KLHL5 NM_015990.4  X  (50) 
LCORL NM_153686.7  X  (50) 
LNX2 NM_015093 X   (50) 
LRIF3 (C1orf103) NM_018372.3  X X (50) 
LRRC59 NM_018509.3 X   (50) 
LSM14A NM_001114093.1 X   (50) 
MAP3K10 NM_002446.3 X   (50) 
MAP3K14 NM_003954.2 X   (50) 
MASTL NM_001172303.1  X  (50) 
MBNL3 NM_018388.3 X   (50) 
MCM8 NM_032485.4  X  (50) 
MED13L NM_015335.4  X  (50) 
MEF2A NM_005587.2 X   (50) 
MORC3 NM_015358.2  X  (50) 
MPP5 NM_022474.2  X  (50) 
MRPL18 NM_014161.3  X  (50) 
MRPS27 NM_015084.2  X  (50) 
MYBL1 NM_001080416.2 X   (50) 
MYD88 NM_001172567  X  (74)  
MYO10 NM_012334 X   (57)  
MYO1D NM_015194.1 X   (50) 
MYST3 NM_001099412.1  X X (50) 
NARS NM_004539.3  X  (50) 
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PAK2 NM_002577.4 X   (50) 
PCDH9 NM_203487.2 X   (50) 
PDCD4 NM_014456.3  X  (50) 
PHC2 NM_198040.2 X   (50) 
PHF14 NM_014660.3  X  (50) 
PHF17 NM_199320.2 X   (50) 
PICALM NM_007166  X  (50; 52)  
PKN2 NM_006256.2 X   (50) 
POLE3 NM_017443.4  X  (50) 
PRKAR1A NM_002734.3 X   (50) 
RAB11FIP2 NM_014904.2 X   (50) 
RAC1 NM_006908.4  X  (50) 
RAPGEF2 NM_014247.2  X  (50) 
RHEB NM_005614.3 X   (50) 
RHOA NM_001664  X X (32)  
RIPK1 NM_003804  X X (61)  
RNF123 (KPC1) NM_022064 X   (75)  
SAP30L NM_024632.5 X   (50) 
SATB1 NM_002971.3 X   (76)  
SDCBP NM_005625.3 X   (50) 
SECISBP2 NM_024077.3  X  (50) 
SKI NM_003036 X   (77)  
SLA  NM_001045556 X   (52)  
SLC33A1 NM_004733.3 X   (50) 
SLC35F2 NM_017515.4  X  (50) 
SMAD1 NM_005900 X   (57)  
SMAD2 NM_005901 X   (50; 78)  
SMAD5 NM_005903  X  (51; 57; 79)  
SMARCA4 NM_001128849.1 X   (50) 
SOCS1 NM_003745 X   (20; 75; 80)  
SOX6 NM_017508.2  X  (81)  
SPI1 (PU.1) NM_001080547  X  (52; 82)  
TAB 2 (MAP3K7IP2) NM_015093 X   (50; 72; 83; 84)  
TAF5L NM_014409.3  X  (50) 
TBC1D14 NM_020773.2  X  (50) 
TBCA NM_004607.2  X  (50) 
TCF12 NM_207036.1  X  (50) 
TLE4 NM_007005.3 X   (50) 
TOMM20 NM_014765.2 X   (50) 
TP53INP1 NM_033285 X   (50; 85; 86)  
TRAK1 NM_001042646.1  X  (50) 
TRIP13 NM_004237.3  X  (50) 
TSGA14 NM_018718.1 X   (50) 
TSPAN14  NM_030927.2 X   (50) 
UBQLN1 NM_013438.4  X  (50) 
VPS18 NM_020857.2 X   (50) 
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WEE1 NM_003390 X   (50; 87)  
WHSC1L1 NM_023034.1  X  (50) 
WWC1 NM_001161661.1 X   (50) 
ZKSCAN5 NM_014569.3  X  (50) 
ZNF248 NM_021045.1 X   (50) 
ZNF254 NM_203282.2  X  (50) 
ZNF273 NM_021148.2  X  (50) 
ZNF28 NM_006969.2  X  (50) 
ZNF611 NM_030972.3  X  (50) 
ZNF652 NM_001145365.1 X   (50; 51)  
ZNF83 NM_001105549.1  X  (50) 
 
Table 2 – Validated miR-155 target genes and prediction status by Targetscan 
An extensive literature search identified published validated miR-155 target genes. 
Validation was defined as luciferase reporter assay and at least one other method. 
Prediction of miR-155 targeting was determined using Targetscan (v 6.0), searching for 
conserved sites between human and mouse. Alternative gene names are given in brackets.
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Figure Legends 
Figure 1: Cellular processing and downstream effects of miR-155 in breast cancer.   
The pri-miR-155 RNA hairpin transcript is processed from the RNA transcript of the BIC 
gene. Transcription of BIC is promoted by Smad4, and inhibited by BRCA1. Drosha and 
Pasha proteins process the pri-miR-155 into a 62 nucleotide pre-miR-155, which is 
exported from the nucleus by Exportin-5. This is subsequently processed by the Dicer 
protein into a 22 nucleotide miRNA duplex (16). One strand of the duplex (miR-155*) is 
degraded with the remaining strand becoming the mature miR-155. miR-155 forms a 
complex with Argonaute proteins called the RNA Induced Silencing Complex (RISC), in 
order to inhibit the translation of miR-155 target mRNAs, such as RhoA, FOXO3A and 
SOCS1. The inhibition of target genes by miR-155 in breast cancer can cause such effects 
as an increase in EMT, cell plasticity, cell survival, growth, chemoresistance and 
radioresistance.  
 
Figure 2 - miR-155 target genes involved in cancer-related pathways. 
Validated miR-155 target genes are present in multiple pathways associated with cancer 
and cancer progression, including but not limited to: EMT, proliferation, block of 
differentiation, apoptosis, sustained angiogenesis (46; 47).  Pathway analysis was 
completed using DAVID bioinformatics resource (v 6.7).  
 
